Results 21 to 30 of about 10,911,887 (292)

The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis [PDF]

, 2020
BACKGROUND: Immunoglobulin light chain (AL) amyloidosis is a rare, multi-systemic disorder characterized by two disease processes: an underlying plasma cell dyscrasia that provides the source of pathologic light chains, and the resulting organ ...
Lousada, I, Inaugural Amyloidosis Forum Panelists, .   +1 more
core   +1 more source

Retinitis pigmentosa associated with systemic light chain amyloidosis (AL amyloidosis)

, 2021
Retinitis pigmentosa (RP) or hereditary retinal dystrophy is a rare disease that can be isolated (non-syndromic RP) or associated with other systemic signs (syndromic RP).
Salem Bouomrani, Fahd Saadaoui, Nour Elhouda Ayadi   +2 more
core   +3 more sources

Be SMART About AL Amyloidosis [PDF]

Mayo Clinic Proceedings, 2021
n ...
Palladini, Giovanni, Merlini, Giampaolo
openaire   +4 more sources

Experimental approaches to study cerebral amyloidosis in a transgenic mouse model of Alzheimer's disease [PDF]

, 2004
Misfolding, aggregation and the accumulation of proteins in the brain are common characteristics of diverse age-related neurodegenerative diseases. Each of these neurodegenerative diseases is associated with abnormalities in the folding of a different
Meyer-Lühmann, Melanie
core   +1 more source

Cerebral amyloidosis in a transgenic mouse model of Alzheimer's disease : impact and therapy [PDF]

, 2003
Senile dementia is a diagnostic category that includes all types of cognitive and memory impairments that occur in the elderly. Alzheimer’s disease (AD) is the most common form of dementia, which is characterized by progressive impairments in memory ...
Boncristiano, Sonia
core   +1 more source

Evaluation of peripheral amyloid neuropathy

Неврология, нейропсихиатрия, психосоматика, 2021
Symptoms of peripheral nervous system (PNS) damage are common clinical manifestations of systemic amyloidosis. Peripheral amyloid neuropathy is characterized by a progressive course, leading to the disability of patients; however, the current ...
O. E. Zinovyeva, E. I. Safiulina, N. S. Shcheglova, Z. V. Surnina, A. M. Nosovskiy   +4 more
doaj   +1 more source

A nationwide assessment of hepatocellular adenoma resection: Indications and pathological discordance

Hepatology Communications, EarlyView., 2022
Abstract Hepatocellular adenomas (HCAs) are benign liver tumors associated with bleeding or malignant transformation. Data on the indication for surgery are scarce. We analyzed indications and outcome of patients operated for HCAs < 50 mm compared to HCAs ≥ 50 mm. Changes in final postoperative diagnosis were assessed.
Martijn P. D. Haring, Arthur K. E. Elfrink, Christiaan A. J. Oudmaijer, Paul C. M. Andel, Alicia Furumaya, Nenke de Jong, Colin J. J. M. Willems, Thijs Huits, Julie M. L. Sijmons, Eric J. T. Belt, Koop Bosscha, Esther C. J. Consten, Mariëlle M. E. Coolsen, Peter van Duijvendijk, Joris I. Erdmann, Paul Gobardhan, Robbert J. de Haas, Tjarda van Heek, Hwai‐Ding Lam, Wouter K. G. Leclercq, Mike S. L. Liem, Hendrik A. Marsman, Gijs A. Patijn, Türkan Terkivatan, Babs M. Zonderhuis, Izaak Quintus Molenaar, Wouter W. te Riele, Jeroen Hagendoorn, Alexander F. M. Schaapherder, Jan N. M. IJzermans, Carlijn I. Buis, Joost M. Klaase, Koert P. de Jong, Vincent E. de Meijer, the Dutch Benign Liver Tumor Group, R. B. Takkenberg, J. Verheij, O. M. van Delden, J. I. Erdmann, B. V. van Rosmalen, A. Furumaya, G. Kazemier, D. Ramsoekh, J. N. M. IJzermans, R. A. de Man, M. D. Doukas, M. G. Thomeer, A. J. Klompenhouwer, A. F. M. Schaapherder, M. E. Tushuizen, M. J. Coenraad, A. S. L. P. Crobach, M. C. Burgmans, S. Feshtali, M. M. E. Coolsen, M. Kramer, J. C. Beckervordersandforth, I. V. Samarska, C. van der Leij, R. Miclea, J. H. W. de Wilt, P. B. van den Boezem, E. T. T. L. Tjwa, I. Munsterman, S. Vos, S. van Koeverden, V. E. de Meijer, F. J. C. Cuperus, R. J. de Haas, E. W. Duiker, M. P. D. Haring   +70 more
wiley   +1 more source

Amyloidosis – short review

Journal of Medical Science, 2016
Amyloidosis is a heterogeneous group of disorders associated with pathological deposition of amyloid. We can recognize two major categories of amyloidosis: primary (AL) and secondary (AA) type.
Agnieszka Danuta Gaczkowska, Paweł Jagodziński, Adrianna Mostowska   +2 more
doaj   +1 more source

Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease

Hematology/Oncology and Stem Cell Therapy, 2019
Introduction: Systemic light chain (AL) amyloidosis can lead to an acquired coagulopathy secondary to acquired factor X (aFX) deficiency. However, it is not very clear who develops aFX deficiency in AL amyloidosis.
Gina Patel, Parameswaran Hari, Aniko Szabo, Lisa Rein, Lisa Baumann Kreuziger, Saurabh Chhabra, Binod Dhakal, Anita D’Souza   +7 more
doaj   +1 more source

Strong positive light chain immunostaining in a patient with transthyretin amyloidosis

Hematology, 2023
The two most common systemic amyloidosis types are immunoglobulin light chain (AL) and amyloid transthyretin (ATTR) amyloidosis, in which the precursor proteins responsible for amyloidosis are light chain and transthyretin, respectively.
Jiao Chen, Haifei Chen, Lingyun Zhou, Danbo Liu, Fang Du, Hongxian Xiang   +5 more
doaj   +1 more source